<DOC>
	<DOC>NCT01311882</DOC>
	<brief_summary>This is a study to evaluate next-day residual effects of MK-4305 on highway driving performance in healthy, non-elderly participants.</brief_summary>
	<brief_title>A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Suvorexant</mesh_term>
	<mesh_term>Zopiclone</mesh_term>
	<criteria>Female participants of reproductive potential must agree to use (and/or have their partner use) acceptable methods of birth control beginning at least 2 weeks prior to the administration of the first dose of study drug throughout the study Has a body mass index (BMI) within the range of 18 to 30 kg/m^2 Possesses a valid driver's license for 3 years or more with at least 5000 km/year on average within the last 3 years Is capable of driving a manual transmission vehicle and is willing to drive on a highway Is judged to be in good health Has a regular sleep pattern Is not visually impaired Has a history of a persistent sleep abnormality Has neurological disease/cognitive impairment Has a history of cataplexy Is a regular user of sedativehypnotic agents Is allergic to zopiclone Has traveled across 3 or more time zones (transmeridian travel) in the last 2 weeks prior to study start and will travel across 3 or more time zones throughout study duration Works a night shift and is not able to avoid night shift work within 1 week before each treatment visit Is pregnant or nursing Does not qualify as a proficient driver according to the driving instructors evaluation of subject's driving on the driving test practice session</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>